Navigation Links
Bedford Laboratories™ to Begin Shipping Dactinomycin for Injection USP 500 mcg (0.5 mg)
Date:7/12/2010

BEDFORD, Ohio,  July 12 /PRNewswire/ -- Bedford Laboratories™, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of  Dactinomycin for Injection USP 500 mcg (0.5 mg) to its comprehensive line of generic oncology products.  Dactinomycin was approved earlier this year by the U.S. Food and Drug Administration (FDA) and is AP rated and equivalent to Cosmegen® by Lundbeck Inc.  Each single dose vial contains 0.5 mg (500mcg) of dactinomycin and 20 mg of mannitol and is individually boxed.  

(Logo:  http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )

Dactinomycin, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms' tumor, childhood rhabdomyosarcoma, Ewing's sarcoma and metastatic nonseminomatous testicular cancer.  Dactinomycin is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia.  Dactinomycin, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies.

Prescribing information is available upon request from the Bedford Laboratories' professional services department at 800.521.5169, or from the company's web site, www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the U.S. and International markets with multisource and specialty injectable products offering a broad range of multisource injectables across multiple therapeutic classes. Bedford Laboratories is one of the largest generic injectable pharmaceutical companies in the US.  For more information on Bedford Laboratories, visit www.bedfordlabs.com.

About Ben Venue Laboratories, Inc.

Ben Venue Laboratories, Inc. (BVL) was founded in 1938 and is a leading contract manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. BVL has been under contract with the National Cancer Institute since 1967 to develop parenteral dosage forms for many anticancer agents. It has also manufactured various AIDS-specific drugs in conjunction with the NCI. BVL is located in Bedford, Ohio and employs more than 1,300 people.  For more information on BVL and current career opportunities, visit www.benvenue.com.

BVL is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.  For more information, please visit http://us.boehringer-ingelheim.com.

Cosmegen® is a registered trademark of Lundbeck Inc.


'/>"/>
SOURCE Bedford Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection
2. Bedford Laboratories(TM) First To Manufacture Generic Indomethacin for Injection USP
3. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
4. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
5. Enrollment Begins on Human PK Study for Medidur(TM) FA
6. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... new report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - ... the North America continued to lead global ... translated into revenues worth US$ 16,907.3 million. ... Asia-Pacific , Latin America , ... anti-bacterial market is inclined towards North America ...
(Date:2/8/2016)... -- Respiratory Devices - Medical Devices Pipeline Assessment, ... report, " Respiratory Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. The report ... comparative analysis of the products at various stages ... in the pipeline product development. It also provides ...
(Date:2/8/2016)... and FAIRFIELD, N.J. , Feb. 8, ... Pharmaceuticals, Inc. (Medimetriks) today announced that they have entered ... commercialization rights for OPA-15406 in the U.S. and ... manufacturing rights.  OPA-15406 is a topical, non-steroidal phosphodiesterase IV ... --> --> In ...
Breaking Medicine Technology:
(Date:2/9/2016)... Texas (PRWEB) , ... February 09, 2016 , ... ... reconstruction firm helping businesses recover after a disaster, announced today the acquisition of ... companies in Hawaii. , “Investing in like-minded companies who excel at ...
(Date:2/9/2016)... ... February 09, 2016 , ... Cirracore ... help enterprises move workloads to the cloud. Cirracore provides a secure VMware® ... without traversing the Internet. Transformation Solutions (TSL Partners) provides a full range ...
(Date:2/9/2016)... ... February 09, 2016 , ... On January 12, 2016 Paul ... appointment after they noticed their furnace not producing any heat. Shortly after entering the ... cracked heat exchanger was leaking dangerous levels of carbon monoxide into the home, at ...
(Date:2/9/2016)... California (PRWEB) , ... February 09, 2016 , ... ... of their new nationwide service to expand access to affordable hearing aids ... million hard of hearing individuals in the United States. , “For the average ...
(Date:2/9/2016)... ... February 09, 2016 , ... United ... In Praise of Prevention,” an animated video designed to prevent the ... translations of the video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, ...
Breaking Medicine News(10 mins):